Table 1.
Baseline characteristics of the study population.
| Combination Therapy | Monotherapy | p Value | ||
|---|---|---|---|---|
| Ezetimibe Add on Statin (n = 13) | Ezetimibe Start with Statin (n = 30) | Statin Monotherapy (n = 90) | ||
| Age (years) | 61.0 (16.5) | 58.5 (11.8) | 58.0 (10.0) | 0.467 |
| Female (%) | 9 (69.2) | 17 (56.7) | 63 (70.0) | 0.398 |
| Diabetes (%) | 2 (15.4) | 3 (10.0) | 10 (11.1) | 0.873 |
| BMI (kg/m2) | 24.0 (6.9) | 24.7 (3.9) | 24.0 (3.7) | 0.658 |
| Glucose, fasting (mg/dL) | 109.0 (27.0) | 105.0 (15.3) | 99.0 (17.0) * | 0.008 |
| Glucose, stimulated (mg/dL) | 123.5 (79.0) | 118.0 (40.0) | 111.0 (30.0) | 0.492 |
| Insulin, fasting (uU/mL) | 7.3 (9.2) | 6.1 (3.1) | 6.2 (3.6) | 0.126 |
| HOMA-IR | 2.0 (2.5) | 1.6 (0.9) | 1.5 (0.9) | 0.060 |
| HbA1c (%) | 6.1 (1.1) | 5.8 (1.0) | 5.9 (0.4) | 0.110 |
| AST (IU/L) | 22.0 (5.5) | 19.5 (6.3) | 21.0 (8.0) | 0.401 |
| ALT (IU/L) | 18.0 (17.5) | 18.5 (7.8) | 18.0 (9.5) | 0.743 |
| Total cholesterol (mg/dL) | 184.0 (38.5) | 259.0 (40.5) * | 232.0 (47.5) *,† | <0.001 |
| Triglycerides (mg/dL) | 113.0 (73.5) | 125.0 (96.5) | 132.0 (68.0) | 0.989 |
| HDL cholesterol (mg/dL) | 50.0 (14.0) | 54.0 (13.5) | 52.0 (15.0) | 0.429 |
| LDL cholesterol (mg/dL) | 112.6 (29.6) | 169.6 (36.2) * | 150.2 (52.0) *,† | <0.001 |
BMI, body mass index; HOMA, homeostatic model assessment; IR, insulin resistance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Kruskal-Wallis test, Dunn procedure; NOTE. Bold text indicates p values < 0.05; * p values < 0.05 vs. ezetimibe add on statin group, by post hoc analyses (Dunn procedure); † p values < 0.05 vs. ezetimibe start with statin group, by post hoc analyses (Dunn procedure), p values < 0.05.